All the Drug Class Drugs
Calcitonin gene-related peptide (CGRP) antagonists.. Fremanezumab 225 mg. PRE-FILL. SYR. (Sol.for S.C. inj.):1, 3×1.5ml.
PRE-FILL PEN (Sol.for S.C. inj.): 1, 3×1.5 ml. Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with fremanezumab.
Two dosing options are avail.:
225 mg once mnthly 675 mg every 3 mnths. (quarter. dosing)
When switch. dosing regimens, the 1st dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiating treatment with fremanezumab, concom. migraine prevent. tmt. may be contin. if consid. necessary by the prescriber .
The tmt. benefit should be assessed within 3 mnths. after initiat. of tmt. Any further decision to cont. tmt. should be taken on an individ. pt. basis. Evaluat. of the need to cont. tmt. is recomm. regularly thereafter.
Missed dose - dosing should resume as soon as possible on the indicat. dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicated for prophylax. of migraine in adults who have at least 4 migraine days per
C/I: Hypersens. react. such as rash, pruritus, urticaria and swell. have been reported uncommon. with fremanezumab. Most react. were reported from within hrs. to one month after admin. and were mild – moder., but some led to discount. or required corticosteroid tmt. If a hypersens. reaction occurs, discount. of fremanezumab admin. should be consid.and appropriate ther. should be initiated.